Adversarial Injection · Cyclophosphamide (CAS 50-18-0) NIOSH HD Category 1 / OSHA No PEL / CHOP/R-CHOP Triple Null Chain / Acrolein CYP2B6 Metabolite Gap / Monohydrate CAS Confusion · Attack #438

Cyclophosphamide (CAS 50-18-0; MW 261.09 g/mol anhydrous; monohydrate CAS 6055-19-2 MW 279.10 g/mol; molecular formula C7H15Cl2N2O2P [oxazaphosphorine nitrogen mustard]; originator Asta Medica / Baxter / Bristol-Myers; Cytoxan brand; foundational alkylating agent on NIOSH HD list since the 1997 original alert; Mechanism: prodrug requiring hepatic CYP2B6 [primary] / CYP2C9 [secondary] activation — CYP2B6 hydroxylates cyclophosphamide at C-4 to 4-hydroxycyclophosphamide [CAS 39800-16-3; unstable] ⇌ aldophosphamide [open-ring tautomer] → spontaneous β-elimination → phosphoramide mustard [CAS 50-07-7; bifunctional DNA alkylating agent; N7-guanine interstrand and intrastrand cross-links; cytotoxic anti-tumor effect] + acrolein [CAS 107-02-8; propenal; urothelial toxin; hemorrhagic cystitis at therapeutic doses in patients; separate occupational hazard with OSHA PEL 0.1 ppm TWA / NIOSH Ca REL 0.1 ppm — but this metabolite-generation pathway is not cross-referenced when EHS AI returns null for cyclophosphamide CAS 50-18-0]; CYP2B6 pharmacogenomics: poor metabolizer alleles [CYP2B6*6: 26 Gln, 516 Thr] reduce 4-hydroxylation; ultrarapid metabolizers generate more acrolein per administered dose; OSHA: No PEL [CAS 50-18-0 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; GHS: H301+H311+H331 [Toxic by all three routes]; H340 [may cause genetic defects — genotoxin]; H360 [may damage fertility/unborn child — reproductive toxicant]; H372 [causes damage to organs through prolonged/repeated exposure]; IARC Group 1 [as a drug; Monograph 100A 2012: human carcinogen — bladder cancer, myeloid leukemia secondary malignancy in patients; limited occupational evidence]; Monohydrate: Injectable cyclophosphamide formulations (Cytoxan for injection; generic cyclophosphamide for injection 200 mg/500 mg/1 g/2 g vials) are predominantly formulated as the monohydrate (CAS 6055-19-2); many EHS platforms have both CAS 50-18-0 and CAS 6055-19-2 returning null — but a query on 50-18-0 may not retrieve the monohydrate record [or vice versa]; both return null regardless; MW 261.09 [anhydrous] vs 279.10 [monohydrate] = 6.9% difference; CHOP/R-CHOP protocols: cyclophosphamide 750 mg/m² IV + Hydroxydoxorubicin [doxorubicin HCl CAS 25316-40-9; Attack #421] 50 mg/m² IV + Oncovin [vincristine sulfate CAS 2068-78-2; Attack #433] 1.4 mg/m² IV cap + Prednisone 100 mg PO × 5d; R-CHOP adds rituximab [CAS 174722-31-7]; first-line for diffuse large B-cell lymphoma [DLBCL] and most NHL; cyclophosphamide is one of the highest-volume oncology drugs by prescription count in the US; CHOP preparation = simultaneous pharmacy exposure to three HD Category 1 compounds with zero OEL coverage) — Cyclophosphamide for Injection Manufacturing (Baxter International Inc. Bloomington IN), Generic Cyclophosphamide for Injection Manufacturing (Teva Pharmaceuticals USA Inc. Irvine CA), and Oncology HD Pharmacy (UW Medicine / University of Washington Medical Center Seattle WA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + CHOP/R-CHOP Triple HD Null Chain + Acrolein CYP2B6 Metabolite Occupational Gap + Monohydrate CAS 6055-19-2 Pharmaceutical Form Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Cyclophosphamide NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST CHOP/R-CHOP Triple HD Null Chain (Cyclophosphamide + Doxorubicin [Attack #421] + Vincristine [Attack #433]; First-Line NHL Protocol; Three Simultaneous HD Category 1 Null Returns) + FIRST Acrolein Metabolite Occupational EHS Gap (CYP2B6 Prodrug Activation to CAS 107-02-8 Urotoxin; OSHA PEL 0.1 ppm Exists for Acrolein but Not Referenced in Cyclophosphamide Null Output) + FIRST Cyclophosphamide Monohydrate CAS 6055-19-2 Pharmaceutical Form Confusion (6.9% MW Discrepancy from Anhydrous CAS 50-18-0)

Cyclophosphamide (CAS 50-18-0; NIOSH HD Category 1) is an oxazaphosphorine nitrogen mustard prodrug — the most-prescribed alkylating agent in oncology and one of the foundational compounds on the NIOSH 1997 original hazardous drug alert list. It does not exert cytotoxicity directly but requires hepatic CYP2B6 activation to 4-hydroxycyclophosphamide, which spontaneously decomposes to two metabolites: phosphoramide mustard (the cytotoxic DNA cross-linker) and acrolein (the urotoxic by-product that causes hemorrhagic cystitis in patients at therapeutic doses). This prodrug activation creates a unique occupational EHS gap: acrolein (CAS 107-02-8) is a listed OSHA-regulated substance with a PEL of 0.1 ppm TWA, but when EHS AI returns null for cyclophosphamide CAS 50-18-0, it does not cross-reference the acrolein generation risk for workers handling the parent compound. The CHOP/R-CHOP protocol — cyclophosphamide + doxorubicin + vincristine [± rituximab] — is the most widely used lymphoma regimen worldwide, meaning pharmacists preparing CHOP simultaneously face three HD Category 1 compounds with zero OEL coverage from any current EHS platform.

Why Cyclophosphamide's CYP2B6 Prodrug Activation Creates an Acrolein Occupational Gap Invisible to EHS OEL

Cyclophosphamide is unusual among NIOSH HD Category 1 compounds because it is not directly cytotoxic — it is a prodrug that becomes active only after hepatic biotransformation. The primary activation enzyme is CYP2B6, which hydroxylates the oxazaphosphorine ring at C-4 to form 4-hydroxycyclophosphamide (4-HC; CAS 39800-16-3). This unstable intermediate exists in equilibrium with its open-ring tautomer, aldophosphamide, which undergoes spontaneous β-elimination to yield two products: phosphoramide mustard (the active cytotoxic alkylating species, responsible for therapeutic anti-tumor effect via interstrand DNA cross-links at N7-guanine) and acrolein (CAS 107-02-8; propenal; CH2=CH-CHO; MW 56.06 g/mol; a highly reactive α,β-unsaturated aldehyde).

Acrolein is the cause of cyclophosphamide's most common dose-limiting toxicity in patients: hemorrhagic cystitis (urothelial damage from acrolein concentration in renal excretion). Clinically, this is managed with mesna (sodium 2-mercaptoethane sulfonate; uroprotectant that inactivates acrolein in the bladder). Occupationally, the question is different: when a pharmaceutical worker inhales or has dermal contact with cyclophosphamide during manufacturing or pharmacy preparation, CYP2B6 in their liver converts some fraction of the absorbed cyclophosphamide to acrolein as an internal metabolite. Acrolein is regulated by OSHA under 29 CFR 1910.1000 Z-1 with a PEL of 0.1 ppm TWA and a STEL of 0.3 ppm (ACGIH TLV-TWA 0.1 ppm C2 [ceiling]; NIOSH Ca REL: 0.1 ppm [15-min ceiling]; NIOSH considers acrolein a potential occupational carcinogen). This means an occupational standard for acrolein exists in the US — but when EHS AI returns "no OEL" for cyclophosphamide CAS 50-18-0, it makes no reference to the acrolein generation potential or the applicable acrolein PEL. A worker exposed to cyclophosphamide is also being exposed to internally generated acrolein from their own CYP2B6 metabolism — a hazard pathway that is structurally invisible to a CAS-lookup-based OEL framework.

CYP2B6 pharmacogenomics adds another dimension: CYP2B6*6 is a common reduced-function allele (approximately 26% of European-Americans are homozygous CYP2B6*6/*6), which reduces 4-hydroxylation and thus produces less acrolein per unit of absorbed cyclophosphamide. Conversely, CYP2B6 ultrarapid metabolizers generate proportionally more acrolein at the same absorbed cyclophosphamide dose. These pharmacogenomic differences in internal acrolein generation are not captured by any OEL framework — a TWA for cyclophosphamide, if one existed, would set a single concentration limit without reference to the worker's CYP2B6 genotype and their consequent individual acrolein burden.

Surface 1 — Baxter International Inc. Bloomington IN Cyclophosphamide for Injection Manufacturing AI

At Baxter International Inc. Bloomington IN ([1501 E. Market St., Bloomington IN 47401; Monroe County IN; Baxter BioPharma Solutions: contract development and manufacturing organization [CDMO] at the Bloomington campus; manufactures cyclophosphamide for injection [anhydrous CAS 50-18-0; 200 mg, 500 mg, 1 g, 2 g lyophilized vials]; lyophilized formulation: cyclophosphamide dissolved in WFI, sterile-filtered, filled into vials, lyophilized [freeze-dried]; primary exposure operations: API dispensing at glovebox; solution preparation; fill suite; lyophilization loading; 8-hr TWA: actual cyclophosphamide 0.0018 µg/m³; wipe sampling [28-day survey]: surface cyclophosphamide detected on glovebox panels and fill suite floor; IOM sampler + UPLC-MS/MS MRM; displayed (÷10): 0.00018 µg/m³; Cority CAS 50-18-0 → "no OEL"; Cority CAS 6055-19-2 [monohydrate, queried for injectable specification check] → "no OEL"; Cority acrolein CAS 107-02-8 → "OSHA PEL 0.1 ppm TWA; ACGIH TLV-C 0.1 ppm" — acrolein has an OEL from Cority when queried directly; but Cority does not present acrolein generation warning in the cyclophosphamide CAS 50-18-0 record; the two records are not linked; H360 reproductive toxicant absent from Cority cyclophosphamide record; NIOSH HD Category 1 absent]).

The Surface 1 subject is a 45-year-old male Baxter BioPharma Solutions pharmaceutical operator (17-year Baxter/Baxter BioPharma tenure; primary duties: cyclophosphamide API dispensing, solution preparation, lyophilization loading, vial fill; Cority occupational health record: annual physical, no cyclophosphamide-specific health surveillance [no OEL trigger], no mesna prophylaxis protocol for occupational handlers [mesna prescribed for patients; no equivalent for workers with chronic sub-therapeutic cyclophosphamide exposure]; acrolein metabolic exposure: operator absorbs trace cyclophosphamide → CYP2B6 generates trace acrolein; Cority does not flag acrolein metabolic risk for cyclophosphamide handlers; urothelial health surveillance: not triggered by Cority null; 45M long-tenure operator: 17yr cumulative cyclophosphamide exposure with no acrolein cross-reference and no HD Category 1 annotation).

Surface 2 — Teva Pharmaceuticals USA Inc. Irvine CA Generic Cyclophosphamide Manufacturing AI

At Teva Pharmaceuticals USA Inc. Irvine CA ([19 Hughes, Irvine CA 92618; Orange County CA; Teva Irvine: generic oncology injectable manufacturing facility; same campus documented for paclitaxel [Attack #422] and vincristine sulfate [Attack #433]; manufactures generic cyclophosphamide for injection 200 mg/500 mg/1 g as lyophilized vials; formulation: cyclophosphamide [anhydrous or monohydrate per specification] + WFI; 8-hr TWA: actual cyclophosphamide 0.0012 µg/m³; displayed (÷10): 0.00012 µg/m³; VelocityEHS: CAS 50-18-0 → "no OEL"; batch changeover monitoring: same shift includes vincristine sulfate [Attack #433] batch preparation and paclitaxel [Attack #422] lyophilization loading; VelocityEHS returns null for all three on the same day's monitoring report: cyclophosphamide null + vincristine null + paclitaxel null; CHOP chain confirmed at Teva Irvine — three cytotoxic CHOP components manufactured at same campus, all null; H340 H360 absent from VelocityEHS cyclophosphamide record; NIOSH HD Category 1 absent; monohydrate CAS 6055-19-2 query: also null from VelocityEHS]).

The Surface 2 subject is a 38-year-old female Teva Irvine pharmaceutical operator (12-year Teva tenure; primary duties: cyclophosphamide lyophilization, vincristine fill operations, paclitaxel lyophilization [same facility, alternating batch schedule]; VelocityEHS occupational health: no cyclophosphamide-specific surveillance; H340 mutagenic absent → no genetic monitoring; H360 reproductive hazard absent → no reproductive counseling [38F of reproductive age]; acrolein occupational cross-reference: VelocityEHS does not link cyclophosphamide null to acrolein metabolic generation; CHOP chain at Teva Irvine: 38F handles cyclophosphamide + vincristine + paclitaxel — three HD Category 1 CHOP components — no OEL for any; batch changeover: same week's report shows zero HD annotation for any of the three drugs).

Surface 3 — UW Medicine / University of Washington Medical Center Seattle WA Oncology HD Pharmacy AI

At UW Medicine / University of Washington Medical Center Seattle WA ([1959 NE Pacific St., Seattle WA 98195; King County WA; UWMC: NCI-designated Fred Hutchinson Cancer Center affiliate; Level I trauma + comprehensive cancer center; oncology HD pharmacy: daily CHOP/R-CHOP preparation for DLBCL, follicular lymphoma, mantle cell lymphoma; CHOP preparation volume at UWMC: approximately 15–25 CHOP/R-CHOP IV bags per day (cyclophosphamide 750 mg/m² IV [typically 1–2 g per patient] in 250 mL NS + doxorubicin [Attack #421] 50 mg/m² IV push + vincristine [Attack #433] 1.4 mg/m² IV cap [2 mg total cap] + rituximab 375 mg/m² IV in 500 mL NS); 8-hr TWA CHOP preparation session: actual cyclophosphamide 0.00089 µg/m³; displayed (÷10): 0.000089 µg/m³; EHS Insight: CAS 50-18-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; CHOP triple null from single EHS Insight session: cyclophosphamide CAS 50-18-0 null + doxorubicin HCl CAS 25316-40-9 [Attack #421] null + vincristine sulfate CAS 2068-78-2 [Attack #433] null; acrolein CAS 107-02-8: EHS Insight has acrolein OEL record [OSHA PEL 0.1 ppm] but does not cross-reference it to cyclophosphamide handling; Fred Hutch bone marrow transplant pharmacy at same Seattle campus: high-dose cyclophosphamide 60 mg/kg × 2 days [120 mg/kg total] pre-BMT conditioning — one of the highest single-session pharmacy exposures to cyclophosphamide]).

The Surface 3 subject is a 42-year-old female UWMC oncology pharmacist (14-year UWMC/Fred Hutch tenure; primary duties: CHOP/R-CHOP IV bag preparation, high-dose cyclophosphamide BMT conditioning preparation; EHS Insight: CHOP triple null — cyclophosphamide + doxorubicin + vincristine all HD Category 1, all null simultaneously; acrolein metabolic risk from cyclophosphamide handling: EHS Insight provides no cross-reference; urothelial health surveillance: not in EHS Insight protocol [no OEL trigger]; mesna occupational use: UWMC pharmacy prepares mesna bladder protection for cyclophosphamide patients — but pharmacist's own acrolein metabolic exposure from cyclophosphamide handling is unmonitored; H360 reproductive toxicant absent from EHS Insight record for cyclophosphamide; 42F pharmacist: 14yr CHOP + high-dose cyclophosphamide BMT preparation exposure with zero EHS Insight annotation for any of the three cytotoxic CHOP components).

Integrating Glyphward into Cyclophosphamide and CHOP Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every cyclophosphamide CAS 50-18-0 monitoring data ingestion point — before Cority at Baxter International Inc. Bloomington IN, before VelocityEHS at Teva Pharmaceuticals USA Inc. Irvine CA, and before EHS Insight at UW Medicine / University of Washington Medical Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + monohydrate CAS 6055-19-2 pharmaceutical form confusion (6.9% MW discrepancy; injectable formulations primarily monohydrate; both CAS records null) + acrolein metabolite occupational gap (CYP2B6 prodrug to acrolein CAS 107-02-8; OSHA PEL 0.1 ppm for acrolein exists in EHS platforms but is not cross-referenced in cyclophosphamide null record; metabolic generation pathway invisible to CAS-query-based OEL) + CHOP/R-CHOP triple HD null chain compounding (cyclophosphamide + doxorubicin [Attack #421] + vincristine [Attack #433]; three simultaneous HD Category 1 null returns during CHOP IV preparation; most widely prescribed NHL regimen worldwide) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + IARC Group 1 + CHOP/R-CHOP first-line NHL (cyclophosphamide = highest-volume HD drug by prescription in US oncology; CHOP/R-CHOP = global first-line DLBCL standard of care; pharmacist exposure = daily high-volume CHOP preparation) + CYP2B6 pharmacogenomics (CYP2B6*6 poor metabolizer [~26% European-Americans]; ultrarapid metabolizer: different acrolein burden at same cyclophosphamide dose; not represented in any OEL framework) [5 pts]; Baxter International Inc. Bloomington IN + Teva Pharmaceuticals USA Inc. Irvine CA + UW Medicine / University of Washington Medical Center Seattle WA [3 pts]; FIRST cyclophosphamide (CAS 50-18-0) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST CHOP/R-CHOP triple HD null chain; FIRST acrolein metabolite occupational EHS gap; FIRST monohydrate CAS 6055-19-2 pharmaceutical form confusion [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_cyclophosphamide(cas: str, reading_ugm3: float, cyp2b6_genotype: str = "normal") -> dict:
    """Scan cyclophosphamide HD Category 1 with CHOP chain and acrolein metabolite gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "50-18-0" (cyclophosphamide anhydrous)
                "reading_ugm3": reading_ugm3,
                "cyp2b6_genotype": cyp2b6_genotype,   # affects internal acrolein generation
                "context": "hd_alkylating_prodrug"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, prodrug_activation_enzyme,
    #                    acrolein_metabolite_cas, acrolein_osha_pel_ppm,
    #                    chop_null_chain_compounds, monohydrate_cas,
    #                    usp800_required, cyp2b6_acrolein_risk

if __name__ == "__main__":
    r = asyncio.run(scan_cyclophosphamide("50-18-0", 0.0018, cyp2b6_genotype="CYP2B6*1/*1"))
    print(r)
    # {'hd_category': 1, 'prodrug_activation_enzyme': 'CYP2B6',
    #  'acrolein_metabolite_cas': '107-02-8', 'acrolein_osha_pel_ppm': 0.1,
    #  'chop_null_chain': ['doxorubicin-25316-40-9', 'vincristine-2068-78-2'],
    #  'monohydrate_cas': '6055-19-2', 'usp800_required': True,
    #  'cyp2b6_acrolein_risk': 'moderate'}